Coloplast upholds growth guidance despite slightly disappointing revenue
Coloplast maintains its expectations for both organic growth and profit margin for the financial year 2023/24. However, the estimate for reported growth in Danish kroner has been revised downwards due to currency headwinds.
This is stated in Coloplast’s financial statements for its second quarter of 2023/24, which were published on Tuesday morning.
For the full year, Coloplast still expects organic growth of around 8% and that the EBIT margin before special items will be in the range of 27-28%.
Growth in Danish kroner is now expected to be 10-11% compared to previously around 11%, and a negative effect from currency headwinds of 1-2 percentage points compared to previously 1 percentage point is expected.
Table of Coloplast’s financial statements for the second quarter of 2023/24. Figures in DKK(m).
| Q2 23/24 |
Q2 23/24 (e) |
Q2 2022/23 |
FY 23/24 (e) |
FY 2022/23 |
|
| Revenue | 6586 | 6693 |
6061 |
27.171 |
24.500 |
| - Ostomy |
2281 |
2358 |
2204 |
9649 |
9000 |
| - Bladder & Bowel |
2062 |
2092 |
1964 |
8492 |
8000 |
| - Urology |
698 |
700 |
667 |
2868 |
2700 |
| - Wound care | 1018 |
1026 |
747 |
4057 |
2900 |
| - Respiratory care |
527 |
518 |
667 |
2098 |
1900 |
| Organic growth (%) |
8 |
7,6 |
8 |
8,1 |
8 |
| EBIT before special items |
1791 |
1840 |
1671 |
8589 |
6845 |
| EBIT margin before special items (%) |
27 |
27,5 |
28 |
29,0 |
28 |
| Pre-tax result |
1607 |
1656 |
1461 |
7967 |
6025 |
| Net result |
1252 |
1292 |
1155 |
6189 |
4783 |
(Translated using DeepL with additional editing by Catherine Brett)
